Boston, MA 04/03/2014 (wallstreetpr) – CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company focusing on oncology, announced that it will present the results obtained from an in-vivo study of aldoxorubicin at the American Association for Cancer Research Annual Meeting.
Positive Phase 2 Results
CytRx Corporation (NASDAQ:CYTR) seeks to present the detailed results of the positive outcome from the study which was conducted in an animal representation of glioblastoma at the AACRAM which will be held from between April 5 and April 9 in San Diego, CA. The data from the trail demonstrate that aldoxorubicin increased survival by more than twice as compared to doxorubicin treatment. The trail deployed a model of in vivo xenograft tumor featuring glioblastoma multiforme (GBM) tumors in the brains of mouse. Aldoxorubicin showed preferential accumulation as well as prolonged retention in the tumor tissue, which is not observed with doxorubicin. Along with the safety profile of aldoxorubicin, these data give way to its development as a treatment for GBM tumors in patients.
Superiority Over Doxorubicin
CytRx Corporation (NASDAQ:CYTR) is conducting a Phase 2 trial to analyze the effectiveness of aldoxorubicin in patients in the later stages of GBM. Towards the end of the previous year, the company had reported obtaining impressive results in its global Phase 2 clinical trial which was based on analyzing aldoxorubicin as a first line treatment in those who had soft tissue sarcomas. Aldoxorubicin was seen to demonstrate from 80% to 100% superiority in progression-free survival after the trail when the results were compared with doxorubicin. Statistical results marking median and 6 month PFS showed high preference of aldoxorubicin therapy over doxorubicin.
The company is also studying aldoxorubicin in a Phase 2 trial in the treatment of HIV related Kaposi’s sarcoma. Apart from this, as part of a special protocol analysis, CytRx Corporation (NASDAQ:CYTR) has also started a pivotal Phase 3 trial with aldoxorubicin as a treatment for patients having soft tissue sarcomas.
